Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov 6:16:1067-1074.
doi: 10.2147/TCRM.S271184. eCollection 2020.

Efficacy of Topical Nepafenac 0.3% in the Management of Postoperative Cystoid Macular Edema

Athanassios K Giarmoukakis #  1 , Styliani V Blazaki #  1 , Georgios C Bontzos  1 , Argyro D Plaka  1 , Konstantinos N Seliniotakis  1 , Larissa D Ioannidi  1 , Miltiadis K Tsilimbaris  1
Affiliations

Efficacy of Topical Nepafenac 0.3% in the Management of Postoperative Cystoid Macular Edema

Athanassios K Giarmoukakis et al. Ther Clin Risk Manag. .

Abstract

Purpose: To assess the effect of twice-daily nepafenac ophthalmic suspension 0.3% on postoperative cystoid-macular-edema (CME).

Patients and methods: In this prospective, clinic-based, non-randomized case-series, 21 patients (21 eyes) were enrolled with either acute or chronic postoperative CME after cataract extraction. Patients were treated with twice-daily nepafenac 0.3% drops, and followed for at least a 4-month period. Best-corrected visual acuity (BCVA) and spectral-domain optical coherence tomography (SD-OCT)-derived central retinal thickness (CRT) were measured.

Results: From 21 patients, eight presented with acute postoperative CME and 13 with chronic CME. Mean follow-up was 4.82±1.24 months. No adverse events were reported during the study. Baseline BCVA was 0.49±0.36 logMAR and improved to 0.36±0.42 logMAR at the last follow-up visit (P<0.005). CRT decreased from 450.40±90.74 μm at baseline to 354.60±81.49 μm (P<0.05), following treatment.

Conclusion: Our outcomes strongly suggest that administrating nepafenac 0.3% drops on a twice-daily regimen could be a promising alternative for the management of postoperative CME. Additional studies are necessary to further validate our results.

Keywords: cataract operation; nepafenac; postoperative macular edema; topical use; treatment.

PubMed Disclaimer

Conflict of interest statement

Miltiadis K Tsilimbaris reports grants, personal fees from Novartis Hellas, personal fees from Bayer Hellas, grants, personal fees from Allergan Hellas, grants from Alcon Hellas, outside the submitted work. The authors report no other potential conflicts of interest for this work.

Figures

Figure 1
Figure 1
Changes in best corrected visual acuity (BCVA) in acute and chronic cystoid macular edema (CME) prior to and after treatment of patients. Statistical significance, P<0.05.
Figure 2
Figure 2
Changes in central retinal thickness (CRT) in acute and chronic cystoid macular edema (CME) prior to and after treatment of patients. Statistical significance, P<0.05.
Figure 3
Figure 3
Patient with acute pseudophakic ME before nepafenac administration and after 4 months therapy. Visual acuity elevated from 0.44 logMAR to 0.30 logMAR, and central macular thickness decreased from 601 μm to 379 μm. Green line represents the same area of the fovea prior to and after therapy in infrared picture, which corresponds to CME improvement.
Figure 4
Figure 4
Patient with chronic CME. CME before nepafenac administration and after 4 months therapy. Visual acuity changed from 0.50 logMAR to 0.30 logMAR, and central macular thickness decreased from 499 μm to 255 μm. Green line represents the same area of the fovea prior to and after therapy in infrared picture, which corresponds to CME improvement.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Gass JD, Norton EW. Fluorescein studies of patients with macular edema and papilledema following cataract extraction. Trans Am Ophthalmol Soc. 1966;64:232–249. - PMC - PubMed
    1. Irvine AR. Cystoid maculopathy. Surv Ophthalmol. 1976;21:1–17. doi:10.1016/0039-6257(76)90045-X - DOI - PubMed
    1. Loewenstein A, Zur D. Postsurgical cystoid macular edema. Dev Ophthalmol. 2010;47:148–159. - PubMed
    1. Chu CJ, Johnston RL, Buscombe C, Sallam AB, Mohamed Q, Yang YC; United Kingdom Pseudophakic Macular Edema Study Group. Risk factors and incidence of macular edema after cataract surgery: a database study of 81984 eyes. Ophthalmology. 2016;123(2):316–323. doi:10.1016/j.ophtha.2015.10.001 - DOI - PubMed
    1. Shimura M, Yasuda K, Nakazawa T, et al. Panretinal photocoagulation induces pro-inflammatory cytokines and macular thickening in high-risk proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2009;247:1617–1624. - PubMed